Asarfi Hospital Limited · BSE:ASARFI
Asarfi Hospital — H1 FY2025 Earnings Presentation
30 slides from Asarfi Hospital's earnings presentation, Oct 30, 2024
Slide 1: Asarfi Hospital Limited - Investor Presentation Cover Letter to BSE
असफ हॉ ीटल सबके िलए ा AHL/AO/2024/0611 Date: 30.10.2024 To The BSE Limited The Listing Department 25th Floor, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001 Sub: Investor Presentation Ref: - Scrip Code: 543943 Dear Sir/ Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Di
Slide 2: Investor Presentation H1 FY2025
Investor Presentation H1 FY2025
Slide 3: Agenda
Agenda Consolidated Financial Snapshot – H1’FY25 Standalone Financial Snapshot – H1’FY25 Competitive Strengths & Key Growth Drivers Consolidated Performance Highlights – H1’FY25 Vision 2026 Standalone Performance Highlights – H1’FY25 Board of Directors and Key Managerial Personnel Asarfi Hospital :
Slide 4: Abbreviations
Abbreviations ACI Asarfi Cancer Institute ARPOB Average Revenue Per Occupied Bed AHL Asarfi Hospital Ltd ALOS Average Length of Stay BCCL Bharat Coking Coal Ltd CAGR Compound Annual Growth Rate BSE Bombay Stock Exchange EBIT Earnings Before Interest and Taxes CCU Cardiac Care Unit EBITDA Earnings Be
Slide 5: Consolidated Financial Snapshot
Consolidated Financial Snapshot Half-Yearly (Consolidated) Performance - H1’FY25 (H1’FY25) Consolidated Revenues at ₹ 5,378.4 Lakhs in H1’FY25 vs ₹ 4,031.7 Lakhs in H1’FY24, grew by 33.4% on a Y-o-Y basis. Consolidated EBITDA at ₹ 1,152.1 Lakhs in H1’FY25 vs ₹ 809.9 Lakhs in H1’FY24, grew by 42.
Slide 6: Standalone Financial Snapshot
Consolidated Financial Snapshot Half-Yearly (Standalone) Performance - H1’FY25 (H1’FY25) Standalone Revenues at ₹ 5,378.4 Lakhs in H1’FY25 vs ₹ 4,031.7 Lakhs in H1’FY24, grew by 33.4% on a Y-o-Y basis. Standalone EBITDA at ₹ 1,162.4 Lakhs in H1’FY25 vs ₹ 809.9 Lakhs in H1’FY24, grew by 43.5% on
Slide 7: Performance Highlights (Consolidated) – H1'FY25
Performance Highlights (Consolidated) – H1’FY25 Revenues (₹ in Lakhs) EBITDA (₹ in Lakhs) 6,000.0 1,400.0 21.4% 22% 5,000.0 1,200.0 20.1% 21% 1,000.0 18.0% 4,000.0 20% 800.0 5,378.4 3,000.0 19% 4,408.3 4,031.7 600.0 2,000.0 18% 400.0 1,152.1 809.9 795.2 1,000.0 200.0 17% 0.0 0.0 16% H1FY24 H2FY24 H1
Slide 8: Performance Highlights (Standalone) – H1'FY25
Performance Highlights (Standalone) – H1’FY25 Revenues (₹ in Lakhs) EBITDA (₹ in Lakhs) 9,000.0 19.4% 25.0% 1,800.0 19.1% 21.6% 25.0% 20.5% 8.5% 19.5% 20.1% 8,000.0 1,600.0 18.1% 16.5% 7,000.0 20.0% 1,400.0 20.0% 6,000.0 1,200.0 15.0% 15.0% 5,000.0 1,000.0 4,000.0 800.0 10.0% 10.0% 3,000.0 600.0 1,0
Slide 9: Asarfi Hospital: At a Glance
Asarfi Hospital : At a Glance Asarfi Hospital Limited (AHL), Established in 2008, is a key multi-specialty tertiary healthcare service provider in the Dhanbad Area which was founded and managed by first-generation entrepreneurs Mr. Harendra Singh, Mr. Nayan Prakash Singh, and Mr. Udai Pratap Singh.
Slide 10: Departments and Facilities
Departments and Facilities General Paediatrics & General Cardiology Neurosciences Obstetrics & medicine Neonatology Surgery Gynaecology Gastroenterology Orthopaedics Burn & Plastic Oncology Nephrology Urology Surgery Ophthalmology ENT Day Care Dental Sciences Physiotherapy Emergency services Nutriti
Slide 11: Asarfi's New Cancer Institute
Asarfi’s New Cancer Institute • With a mission to provide comprehensive, state-of-the-art cancer care with a holistic approach that encompasses medical expertise, emotional support, and cutting-edge technology, Asarfi Hospital laid down the foundations for the construction of its new Cancer Institut
Slide 12: Operational Highlights - H1'FY25 (1/2)
Operational Highlights - H1’FY25 (1/2) For the half-year ended September 2024, AHL reported revenue of Rs. 4,675.1 lakhs from its Super Multi-Specialty Hospital (Baramuri), Rs. 613.0 lakhs from its cancer hospital (Ranguni), Rs. 72.7 lakhs from SRT Labs and 16.9 lakhs from Nursing courses, total r
Slide 13: Operational Highlights – H1'FY25 (2/2)
Operational Highlights – H1’FY25 (2/2) IPD-OPD Volumes IPD-OPD Revenues (In Rs Lakhs) 1,00,000 89,087 8,000 7,061 7,000 6,128 80,000 70,868 5,628 65,563 6,000 60,000 54,278 5,000 4,423 43,598 4,000 3,406 40,000 3,000 2,000 1,379 20,000 9,554 840 942 625 865 7,503 8,036 4,565 6,027 1,000 - - FY22 FY2
Slide 14: Revenue Mix H1'FY25 Vs H1'FY24 (1/2)
Revenue Mix H1’FY25 Vs H1’FY24 (1/2) Cardiology Neurosciences 2.2% 2.3% 0.7% 3.0% General Medicine 2.6% 1.3% Paediatrics & Neonatology 1.6% 11.5% General Surgery 4.3% 28.4% 24.8% Obstetrics & Gynaecology Orthopaedics 5.1% Pulmonology 3.4% Oncology Department-wise Urology Department-wise Revenue 7.2%
Slide 15: Revenue Mix H1'FY25 Vs H1'FY24 (2/2)
Revenue Mix H1’FY25 Vs H1’FY24 (2/2) 5.3% 6.5% 25.1% 18.9% Segment-wise Segment-wise Revenue Mix Revenue Mix H1’FY25 H1’FY24 59% 9.0% 65.6% 11.1% IPD OPD IPD Pharmacy OPD Pharmacy IPD OPD IPD Pharmacy OPD Pharmacy 14
Slide 16: Profit & Loss Account (Consolidated) – H1'FY25
Profit & Loss Account (Consolidated) – H1’FY25 (₹ in Lakhs) Particulars FY24 H1FY24 H2FY24 H1FY25 Revenue 8,440.0 4,031.7 4,408.3 5,378.4 Other Income 167.0 87.9 79.1 180.6 Total Income 8,607.1 4,119.6 4,487.4 5,558.9 Yoy Revenue Growth % 19.4% - - 33.4% Cost of Goods Sold (2,032.1) (954.0) (1,078.0
Slide 17: Profit & Loss Account (Standalone) – H1'FY25
Profit & Loss Account (Standalone) – H1’FY25 (₹ in Lakhs) Particulars FY22 FY23 FY24 H1FY24 H2FY24 H1FY25 Revenue 6,519.0 7,070.0 8,440.0 4,031.7 4,408.3 5,378.4 Other Income 98.2 233.0 167.0 87.9 79.1 180.6 Total Income 6,617.2 7,303.0 8,607.1 4,119.6 4,487.4 5,558.9 Yoy Revenue Growth % 20.5% 8.5%
Slide 18: Balance Sheet (Consolidated) – H1'FY25
Balance Sheet (Consolidated) – H1’FY25 (₹ in Lakhs) Particulars FY24 H1’FY24 H1’FY25 Total Shareholders Funds 7,040.7 6,802.2 7,451.8 Total Non-Current Liabilities 4,220.2 4,405.0 5,138.7 (Long-term Borrowings & Other NCL) Total Sources of Funds 11,260.9 11,207.2 12,590.5 Total Non-Current Assets 10
Slide 19: Standalone Balance Sheet – H1'FY25
Standalone Balance Sheet – H1’FY25 (₹ in Lakhs) Particulars FY22 FY23 FY24 H1’FY24 H1’FY25 Total Shareholders Funds 2,262.8 4,185.6 7,045.8 6,802.2 7,469.7 Total Non-Current Liabilities 2,531.2 3,199.4 4,220.2 4,405.0 5,138.7 (Long-term Borrowings & Other NCL) Total Sources of Funds 4,794.0 7,385.0
Slide 20: Facilities Overview (1/3)
Facilities Overview (1/3) Location: Situated on the Main Highway, 6 km from Dhanbad Railway Station. Building: 4 blocks, 6 floors, constructed area >1 Lacs sq. ft., land area 92 decimals Specialty: Cardiology and Neurology contribute ~50% of revenue. Asarfi Hospital, Baramuri, Dhanbad Bed ca
Slide 21: Facilities Overview (2/3)
Facilities Overview (2/3) Land Details: Leased 9.55 acres (5,06.000 Sq. Ft) of land from Jharkhand Industrial Area Development Authority (JIADA) for 30 years. Bed Capacity: 50 beds across 2 floors, operating at 25% occupancy. Occupancy level: Expected to attain 75% Occupancy level by FY25 Ex
Slide 22: Facilities Overview (3/3)
Facilities Overview (3/3) Location: 4 km from Ranchi Airport, with solid road infrastructure and surrounded by HEC India. Land Details: 5.6 acres (22,662 sq. mtrs) of land acquired at a cost of Rs 13.2 crores (registry pending). As per management, Land value appreciated to ~Rs 65 crores. Land fo
Slide 23: Our Journey
Our Journey • Established Burn Department. 2009 2008 • Installed 10NM3 PSA Oxygen Plant. • Started In Patient • Completed Expansion of Block-A. 2016 Department (IPD). • Increased Bed Strength From 98 to 120 Beds. • Commenced Operation of Cardiac Department. 2017 • Started Construction of Block-B. 20
Slide 24: IPO Proceeds and Utilisation
IPO Proceeds and Utilisation 26.28% 45.32% IPO Proceeds Breakdown of ₹ 7.08 allocated for General ₹ 26.94 Cr Corporate purposes ₹ 12.21 allocated as Capex for Cancer Hospital in Dhanbad 28.40% ₹ 7.65 allocated as Capex for Research Institute in Ranchi The IPO was entirely a fresh issue of 51.8 lak
Slide 25: Competitive Strengths
Competitive Strengths Experienced & highly qualified Regional team of medical Advantage professionals Advanced high-end Track record of stable medical equipment operating and financial and Technology performance Equipped with Stable operating and cutting-edge financial performance AHL boasts a
Slide 26: Expansion Plans
Expansion Plans Introduction of an Establishment of a Launch of educational Strategic capacity IVF vertical in the Bone Marrow courses in law, BCA, expansion: Increasing existing hospital, Transplant unit in the and medical fields, bed capacity in the catering to cancer hospital, leveraging
Slide 27: Key Growth Drivers
Key Growth Drivers Healthcare market in Eastern India is expected to be driven by low penetration of larger hospital chains, high population density, and increasing penetration of health insurance. India's hospital market was valued at Rs. 8.3 Lakh Crore in 2023, projected to grow at a CAGR of 8.0%
Slide 28: Vision 2026
Vision 2026 VISION 2026 23.7% 380 EBITDA CURRENT Beds 21.4% Margin FY26 300 EBITDA FY26 Beds Margin H1’FY25 H1’FY25 29%+ 18% Revenue Revenue 7.7% 11.0% CAGR CAGR PAT Margin PAT Margin Next 2 Years Last 3 Years H1’FY25 FY26 ₹19,524 9.0% ARPOB ROCE ₹19,823 H1’FY25 H1’FY25 15.0% ARPOB ROCE FY26 FY26 27
Slide 29: Board of Directors & Key Managerial Personnel
Board of Directors & Key Managerial Personnel Harendra Singh Udai Pratap Singh Sukanti Kumar Das Promoter & CFO Promoter and MD Non- Executive Director • A visionary entrepreneur inspired by the • Renowned Consultant Gynaecologist Company’s Purpose—Health for All. • Started his career in 2017, he is
Slide 30: Disclosure and Contact Details
Disclosure and Contact Details Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performanc